PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11815669-5 2002 In response to cAMP stimulation by isoproterenol, clearance was inhibited by the CFTR inhibitor glibenclamide in both wild-type mice and the normal human lung. Glyburide 96-109 cystic fibrosis transmembrane conductance regulator Mus musculus 81-85 12392107-5 2002 Glibenclamide, a blocker of the cystic fibrosis transmembrane conductance regulator (CFTR), reduced the MTX-stimulated increase of Isc by 59 +/- 6%. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 32-83 12392107-5 2002 Glibenclamide, a blocker of the cystic fibrosis transmembrane conductance regulator (CFTR), reduced the MTX-stimulated increase of Isc by 59 +/- 6%. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 85-89 11356184-3 2001 Application of a phosphorylating cocktail activated a Cl- current with characteristics similar to those of CFTR mediated currents in other cells types (slow activation by cAMP, absence of rectification, block by glibenclamide). Glyburide 212-225 cystic fibrosis transmembrane conductance regulator Mus musculus 107-111 11675429-1 2001 In vitro studies have shown that glibenclamide sensitivity is conferred upon Kir 1.1 K(+) channels when they are co-expressed with the cystic fibrosis transmembrane conductance regulator (CFTR). Glyburide 33-46 cystic fibrosis transmembrane conductance regulator Mus musculus 135-186 11675429-1 2001 In vitro studies have shown that glibenclamide sensitivity is conferred upon Kir 1.1 K(+) channels when they are co-expressed with the cystic fibrosis transmembrane conductance regulator (CFTR). Glyburide 33-46 cystic fibrosis transmembrane conductance regulator Mus musculus 188-192 11502593-4 2001 Apical addition of 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) or glibenclamide partially inhibited the rise in I(sc) induced by dDAVP and ISO in BAm-treated CFTR(+/+) CCDs, whereas dDAVP, ISO, and NPPB did not alter I(sc) in BAm-treated CFTR(-/-) CCDs. Glyburide 70-83 cystic fibrosis transmembrane conductance regulator Mus musculus 162-166 11502593-4 2001 Apical addition of 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) or glibenclamide partially inhibited the rise in I(sc) induced by dDAVP and ISO in BAm-treated CFTR(+/+) CCDs, whereas dDAVP, ISO, and NPPB did not alter I(sc) in BAm-treated CFTR(-/-) CCDs. Glyburide 70-83 cystic fibrosis transmembrane conductance regulator Mus musculus 242-246 10484343-3 1999 A linear 7-pS Cl- conductance, which is stimulated by ATP and cAMP analogs and inhibited by glibenclamide, consistent with CFTR activity, has been identified in GT1-7 cells. Glyburide 92-105 cystic fibrosis transmembrane conductance regulator Mus musculus 123-127 10562333-13 1999 Glibenclamide (50 microM) significantly blocked ICl,ATP activated by ATPgammaS or by the CFTR channel activator, levamisole. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 89-93 9306276-9 1997 Acidification of the intracellular solution relieved glibenclamide inhibition of CFTR, suggesting that the anionic form of glibenclamide inhibits CFTR. Glyburide 123-136 cystic fibrosis transmembrane conductance regulator Mus musculus 81-85 9490811-12 1998 1-transfected cells were not affected by glibenclamide, whereas glibenclamide did inhibit the conductance expressed in cells co-transfected with CFTR (IC50 = 35.9 +/- 6.6 microM). Glyburide 77-90 cystic fibrosis transmembrane conductance regulator Mus musculus 158-162 9306276-0 1997 Mechanism of glibenclamide inhibition of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in a murine cell line. Glyburide 13-26 cystic fibrosis transmembrane conductance regulator Mus musculus 41-92 9306276-2 1997 The sulphonylurea drug glibenclamide is a widely used inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR). Glyburide 23-36 cystic fibrosis transmembrane conductance regulator Mus musculus 71-122 9306276-2 1997 The sulphonylurea drug glibenclamide is a widely used inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR). Glyburide 23-36 cystic fibrosis transmembrane conductance regulator Mus musculus 124-128 9306276-5 1997 Addition of glibenclamide (10-100 microM) to the intracellular solution caused a concentration-dependent decrease in the open time of CFTR Cl- channels, but closed times did not change. Glyburide 12-25 cystic fibrosis transmembrane conductance regulator Mus musculus 134-138 9306276-6 1997 This suggests that glibenclamide is an open-channel blocker of CFTR. Glyburide 19-32 cystic fibrosis transmembrane conductance regulator Mus musculus 63-67 9306276-9 1997 Acidification of the intracellular solution relieved glibenclamide inhibition of CFTR, suggesting that the anionic form of glibenclamide inhibits CFTR. Glyburide 53-66 cystic fibrosis transmembrane conductance regulator Mus musculus 81-85 9889382-4 1999 6+/-0.2 microM ATP, and that the mechanical stress-induced release of ATP was inhibited by glibenclamide and verapamil, non-specific inhibitors of the cystic fibrosis transmembrane conductance regulator and P-glycoprotein, respectively. Glyburide 91-104 cystic fibrosis transmembrane conductance regulator Mus musculus 151-202 9306276-9 1997 Acidification of the intracellular solution relieved glibenclamide inhibition of CFTR, suggesting that the anionic form of glibenclamide inhibits CFTR. Glyburide 123-136 cystic fibrosis transmembrane conductance regulator Mus musculus 146-150 9306276-12 1997 Glibenclamide inhibition of CFTR was unaffected by nucleotide-dependent stimulation of CFTR, suggesting that glibenclamide and intracellular MgATP interact with CFTR at distinct sites. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 28-32 9306276-14 1997 Glibenclamide inhibition of CFTR was voltage dependent and enhanced when the external Cl- concentration was decreased. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 28-32 9306276-15 1997 The data suggest that glibenclamide and Cl- ions may compete for a common binding site located within a large intracellular vestibule that is part of the CFTR pore. Glyburide 22-35 cystic fibrosis transmembrane conductance regulator Mus musculus 154-158 9277342-10 1997 Channels activated by all activators were inhibited by glibenclamide and a known inhibitory antiserum [anti-CFTR-(505-511)]. Glyburide 55-68 cystic fibrosis transmembrane conductance regulator Mus musculus 108-112 16470247-4 2006 We report here that both ATP and glibenclamide sensitivities of the 30 pS K channel in TAL cells were absent in mice lacking CFTR and in mice homozygous for the deltaF508 mutation. Glyburide 33-46 cystic fibrosis transmembrane conductance regulator Mus musculus 125-129 7510877-7 1993 These results are consistent with murine CFTR being a cAMP-activated chloride channel inhibited by glibenclamide and resistant to DIDS. Glyburide 99-112 cystic fibrosis transmembrane conductance regulator Mus musculus 41-45 30874987-8 2019 However, further addition of glibenclamide, a CFTR channel blocker, abolished lubiprostone-evoked HCO3- secretion. Glyburide 29-42 cystic fibrosis transmembrane conductance regulator Mus musculus 46-50 17395634-8 2007 The cAMP-stimulated Isc component was sensitive to glibenclamide but not to DIDS, suggesting that a cystic fibrosis transmembrane conductance regulator (Cftr)-mediated anion conductance was responsible. Glyburide 51-64 cystic fibrosis transmembrane conductance regulator Mus musculus 100-151 17395634-8 2007 The cAMP-stimulated Isc component was sensitive to glibenclamide but not to DIDS, suggesting that a cystic fibrosis transmembrane conductance regulator (Cftr)-mediated anion conductance was responsible. Glyburide 51-64 cystic fibrosis transmembrane conductance regulator Mus musculus 153-157 18086811-10 2008 In addition, H-89, a cAMP-dependent protein kinase A (PKA) inhibitor, and glibenclamide, a CFTR inhibitor, inhibited fluid accumulation. Glyburide 74-87 cystic fibrosis transmembrane conductance regulator Mus musculus 91-95 21135815-7 2011 Furthermore, mite-infested Cftr(+/+) mice orally administered with a chloride channel inhibitor glibenclamide had higher scratching count and increased level of NGF than vehicle-treated mice. Glyburide 96-109 cystic fibrosis transmembrane conductance regulator Mus musculus 27-31 16760362-5 2006 Glutamate-stimulated ATP release was significantly antagonized by the cystic fibrosis transmembrane conductance regulator (CFTR) blockers flufenamic acid and glibenclamide. Glyburide 158-171 cystic fibrosis transmembrane conductance regulator Mus musculus 70-121 16760362-5 2006 Glutamate-stimulated ATP release was significantly antagonized by the cystic fibrosis transmembrane conductance regulator (CFTR) blockers flufenamic acid and glibenclamide. Glyburide 158-171 cystic fibrosis transmembrane conductance regulator Mus musculus 123-127 16135545-6 2006 Glibenclamide or NPPB reduced the DCEBIO-stimulated Isc by >80% indicating the participation of CFTR in the DCEBIO-stimulated Isc response. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 99-103 16012949-9 2005 CONCLUSIONS: The ability of glibenclamide to stimulate secretion in CFTR-defective mice makes sulfonylureas a model class of compounds to design drugs useful in the treatment of cystic fibrosis with liver impairment and possibly of other cholestatic diseases. Glyburide 28-41 cystic fibrosis transmembrane conductance regulator Mus musculus 68-72 16012949-0 2005 Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 76-127 16012949-3 2005 Glibenclamide, a sulfonylurea and a known CFTR inhibitor, paradoxically stimulates cholangiocyte secretion. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 42-46 16012949-8 2005 Glibenclamide, unlike secretin and forskolin, was able to stimulate secretion in Cftr tm1Unc mice, thus indicating that this secretory mechanism was preserved. Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 81-85 16081479-6 2005 CFTR was activated in myocytes maintained in medium containing either high potassium or 5-hydroxytryptamine (5-HT) and was inhibited by CFTR(inh)-172, glibenclamide and diphenylamine-2,2"-dicarboxylic acid (DPC). Glyburide 151-164 cystic fibrosis transmembrane conductance regulator Mus musculus 0-4 15650130-7 2005 Similarly, treatment of WT epithelium with the CFTR-selective blocker glybenclamide decreased the Cl(-)/HCO(3)(-) exchange rate to the level of CF epithelium. Glyburide 70-83 cystic fibrosis transmembrane conductance regulator Mus musculus 47-51 15306545-6 2004 Glibenclamide, a blocker of CFTR, eliminated the genistein-stimulated increase of I(sc) and reduced the forskolin-activated I(sc). Glyburide 0-13 cystic fibrosis transmembrane conductance regulator Mus musculus 28-32 14978203-7 2004 The I(Cl,ATP) persistently activated by GTPgammaS, was inhibited by glibenclamide but not by DIDS, thus exhibiting known pharmacological properties of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels. Glyburide 68-81 cystic fibrosis transmembrane conductance regulator Mus musculus 151-202 14978203-7 2004 The I(Cl,ATP) persistently activated by GTPgammaS, was inhibited by glibenclamide but not by DIDS, thus exhibiting known pharmacological properties of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels. Glyburide 68-81 cystic fibrosis transmembrane conductance regulator Mus musculus 204-208